Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 3/2016

01-02-2016 | Letter to the Editor

Extinction of myeloproliferative neoplasm by acquisition of a lymphoid disease: JAK2 V617F and JAK2 exon 12 allele burden disappearance during the follow-up of two patients

Authors: Kristell Mahé, Damien Luque Paz, Marie-Anne Couturier, Aurélie Chauveau, Isabelle Quintin-Roué, Christian Berthou, Valérie Ugo, Eric Lippert, Jean-Christophe Ianotto

Published in: Annals of Hematology | Issue 3/2016

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Nishihori T, Hassoun Y, Zhang L, Shain K, Alsina M, Kharfan-Dabaja MA (2014) High-dose melphalan produces favorable response in a patient with multiple myeloma and coexisting essential thrombocythemia with JAK2 mutation. Bone Marrow Transplant 49(1):148–149CrossRefPubMed
2.
Lekovic D, Gotic M, Mitrovic O, Radojkovic M, Bila J, Dencic-Fekete M et al (2013) The emergence of non-secretory multiple myeloma during the non-cytotoxic treatment of essential thrombocythemia: a case report. J Med Case Rep 11(7):224CrossRef
3.
Ben Youssef Y, Gmidène A, Bouabid Z, Bouallegui S, Sriha B, Zaier M et al (2013) Multiple myeloma following essential thrombocythemia. Ann Biol Clin (Paris) 71(4):457–460
4.
Malhotra J, Kremyanskaya M, Schorr E, Hoffman R, Mascarenhas J (2014) Coexistence of myeloproliferative neoplasm and plasma-cell dyscrasia. Clin Lymphoma Myeloma Leuk 14(1):31–36CrossRefPubMed
5.
Gado K, Domjan G, Hegyesi H et al (2000) Role of interleukin-6 in the pathogenesis of multiple myeloma. Cell Biol Int 24:195–209CrossRefPubMed
6.
Laurenti L, Tarnani M, Nichele I, Ciolli S, Cortelezzi A, Forconi F et al (2011) The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: a retrospective multicentric GIMEMA experience. Am J Hematol 86(12):1007–1012CrossRefPubMed
7.
Stijnis C, Kroes WG, Balkassmi S, Marijt EW, van Rossum AP, Bakker E et al (2012) No evidence for JAK2(V617F) mutation in monoclonal B cells in 2 patients with polycythaemia vera and concurrent monoclonal B cell disorder. Acta Haematol 128(3):183–186CrossRefPubMed
8.
Griesshammer M, Grunewald M, Michiels JJ (2003) Acquired thrombophilia in pregnancy: essential thrombocythemia. Semin Thromb Hemost 29(2):205–212CrossRefPubMed
9.
Otsuka M, Hanada S, Arita K, Ohashi H (2014) Spontaneous regression of essential thrombocythemia with MPL mutation on menopause. Int J Hematol 99(5):668–670CrossRefPubMed
10.
Xu C, Cao G, Chen Q et al (2014) Interferon-alpha secreting mesenchymal stem cells exert potent antitumor effect in vivo. Oncogene 33(42):5047–5052CrossRefPubMed
Metadata
Title
Extinction of myeloproliferative neoplasm by acquisition of a lymphoid disease: JAK2 V617F and JAK2 exon 12 allele burden disappearance during the follow-up of two patients
Authors
Kristell Mahé
Damien Luque Paz
Marie-Anne Couturier
Aurélie Chauveau
Isabelle Quintin-Roué
Christian Berthou
Valérie Ugo
Eric Lippert
Jean-Christophe Ianotto
Publication date
01-02-2016
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 3/2016
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-015-2559-9

Other articles of this Issue 3/2016

Annals of Hematology 3/2016 Go to the issue

Letter to the Editor

Hand-foot syndrome following decitabine

Letter to the Editor

Paraneoplastic cerebellar degeneration as an early sign of classical Hodgkin lymphoma

Original Article

Documentation of renal glomerular and tubular impairment and glomerular hyperfiltration in multitransfused patients with beta thalassemia

Letter to the Editor

Immune thrombocytopenic purpurae presenting with cortical vein thrombosis: is it rebalanced hemostasis?

Original Article

Favorable outcome in children and adolescents with a high proportion of advanced phase disease using single/multiple autologous or matched/mismatched allogeneic stem cell transplantations

Letter to the Editor

Remission of remitting seronegative symmetrical synovitis with pitting edema after unrelated cord blood transplantation for myelodysplastic syndrome
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits